ReviewTherapeutic advances in hematology2026
Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy.
Review in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) has poor outcomes and limited salvage options. Objectives: To evaluate the efficacy and safety of daratumumab-based therapy in R/R T-ALL/T-LBL. Design: Systematic review of observational reports. Methods: Sixteen reports including 34 patients treated with daratumumab-based regimens were reviewed. Baseline characteristics, treatment patterns, response, MRD status, survival, allogeneic HSCT, and safety were descriptively synthesized. Results: Complete remission was reported in 30/34 patients (88.2%), partial remission in 2/34 (5.9%), and no response in 2/34 (5.9%). Among complete responders with reported MRD status, 24/29 (82.8%) achieved MRD negativity. Median PFS was 10 months (range, 0.4-45), and median OS was 10 months (range, 1.5-45), although many values reflected last follow-up. Eighteen patients (52.9%) proceeded to allogeneic HSCT; 13/18 (72.2%) were alive at last follow-up. Infusion reactions occurred in 10 patients, mostly grade 1-2. Conclusion: Daratumumab-based therapy may induce remission and facilitate HSCT bridging in selected patients, but findings remain hypothesis-generating because evidence is mainly from case reports and small series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.